Actively Recruiting
Clinical Trial Protocol: Alzheimer's Dementia Underlying Encephalopathy
Led by Covenant Health, US · Updated on 2025-10-29
30
Participants Needed
6
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to determine if the Quest AD-Detect blood test can help diagnose underlying Alzheimer's disease earlier in patients hospitalized with cognitive issues such as delirium or encephalopathy. The study focuses on patients aged 60 to 90 who have no prior diagnosis of dementia but show cognitive impairment possibly related to toxic or metabolic conditions. Researchers want to see if the blood test can distinguish Alzheimer's disease from other causes of cognitive problems in the hospital setting. All eligible patients will have their blood collected and tested using the Quest AD-Detect blood test during their hospital stay. The study involves only one group where every participant receives this diagnostic blood test. There are no placebo or comparison groups in this trial. Participants will be followed up for six months after hospitalization through a Neurology Clinic to discuss their risk assessment results. The main outcome measured is the percentage of patients with a positive biomarker for Alzheimer's dementia among those presenting with cognitive diagnoses. The trial's total duration extends from enrollment to the six-month post-hospital follow-up visit.
CONDITIONS
Brief Title
Clinical Trial Protocol: Alzheimer's Dementia Underlying Encephalopathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ages 60 to 90 years old
- No prior diagnosis of dementia
- Currently hospitalized with cognitive diagnosis, including but not limited to delirium or encephalopathy, thought to be secondary to a toxic or metabolic state
You will not qualify if you...
- Age under 60 years
- Prior diagnosis of dementing illness or other organic cause of cognitive impairment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Day of enrollment
Participants have blood collected for testing using the Quest AD-Detect blood test to assess biomarkers for Alzheimer's dementia.
1 visit (in-person)
Duration - Up to 6 months
Participants are followed for up to 6 months with neurology clinic appointments to monitor cognitive status after diagnostic testing.
1 follow-up visit
Trial Site Locations
Total: 6 locations
1
Cumberland Medical Center
Crossville, Tennessee, United States, 38555
Actively Recruiting
2
Roane Medical Center
Harriman, Tennessee, United States, 37748
Actively Recruiting
3
Fort Sanders Regional Medical Center
Knoxville, Tennessee, United States, 37916
Actively Recruiting
4
Fort Loudon Medical Center
Lenoir City, Tennessee, United States, 37772
Actively Recruiting
5
Methodist Medical Center
Oak Ridge, Tennessee, United States, 37830
Actively Recruiting
6
LeConte Medical Center
Sevierville, Tennessee, United States, 37862
Actively Recruiting
Research Team
C
Clinical Research Nurse Coordinator
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here